Novo's Martin Holst Lange Talks New Weight Loss Shot

from Bloomberg Talks · host Bloomberg

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger. See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Feb 23, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Novo's Martin Holst Lange Talks New Weight Loss Shot

0:00 5:49

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Bloomberg Talks?

This episode is 5 minutes long.

When was this Bloomberg Talks episode published?

This episode was published on February 23, 2026.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this Bloomberg Talks episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!